Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Sep 30, 2021 9:31pm
133 Views
Post# 33950664

RE:RE:RE:RE:Novak ...

RE:RE:RE:RE:Novak ...
porksniffer wrote: This turd is still churning on volume. Shareholders dumping with every bounce. Big holders want out. Mr. Bugs still thinks the 'old' JRG believers are still here. Big instutions are long gone, replaced by others who then also dump when they realize this is going nowhere. I got a good chuckle at #27 fastest growing company. Nearly 1 billion spent 'buying' growth in third world nations is not hard to do. Cash is running low. Organic growth here is pretty much nil and market knows this.


Unfortunately every word is "opinion without  a trace or reality" but it's fun to see you guess wrong.
- those testing the waters and have been trying it over the past few years are the ones in/out.  They are providing the downward pressure but that's expected for a while
- no evidence of big holders wanting out ... as big holders are the ones involved in annual AGM voting and the company shows the voting consistency there every year
- I don't know which big institutions are in and which are out ... but that isn't important to growth ... it's the strategy from within.
- they are 27 due to pure revenue growth from Grupo Biotoscana's purchase (that means nothing) but based on scoring, that's where they ranked.  It just reminds investors we're going from 0 to 60 right now ... foundation has been built and operating revenue is flowing.
- if putting together the only LATAM and Canada reaching pharma at 6% of the world's pharma market isn't hard to do, why haven't you done it ?  Cuz you can't ... and neither could Endo. Hahaha !
- bet you they know exactly where cash is coming from - finance whiz kids.
- they aren't much of an organic growth business as you perceive it ... but they have a lot of drugs still to come to market ... list is out there !  More to be added over time - like they did it before.

Nice try though.  Back to the drawing board for you !!!!
<< Previous
Bullboard Posts
Next >>